171 related articles for article (PubMed ID: 30952590)
1. Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.
Kawamoto Y; Tomino M; Hiramatsu K; Oyama Y; Hayashi Y
Bioorg Med Chem Lett; 2019 Jun; 29(11):1419-1422. PubMed ID: 30952590
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.
Hamaguchi W; Masuda N; Isomura M; Miyamoto S; Kikuchi S; Amano Y; Honbou K; Mihara T; Watanabe T
Bioorg Med Chem; 2013 Dec; 21(24):7612-23. PubMed ID: 24238902
[TBL] [Abstract][Full Text] [Related]
3. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
[TBL] [Abstract][Full Text] [Related]
4. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
[TBL] [Abstract][Full Text] [Related]
5. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
[TBL] [Abstract][Full Text] [Related]
6. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.
Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ
Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491
[TBL] [Abstract][Full Text] [Related]
7. Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors.
Geneste H; Drescher K; Jakob C; Laplanche L; Ochse M; Torrent M
Bioorg Med Chem Lett; 2019 Feb; 29(3):406-412. PubMed ID: 30587449
[TBL] [Abstract][Full Text] [Related]
8. Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.
Varnes JG; Geschwindner S; Holmquist CR; Forst J; Wang X; Dekker N; Scott CW; Tian G; Wood MW; Albert JS
Bioorg Med Chem Lett; 2016 Jan; 26(1):197-202. PubMed ID: 26597534
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
[TBL] [Abstract][Full Text] [Related]
10. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
12. Novel triazines as potent and selective phosphodiesterase 10A inhibitors.
Malamas MS; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Hage T; Ni Y; Erdei J; Fan KY; Parris K; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Brandon NJ; Hoefgen N
Bioorg Med Chem Lett; 2012 Sep; 22(18):5876-84. PubMed ID: 22902656
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors.
Dore A; Asproni B; Scampuddu A; Pinna GA; Christoffersen CT; Langgård M; Kehler J
Eur J Med Chem; 2014 Sep; 84():181-93. PubMed ID: 25016376
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.
Rzasa RM; Frohn MJ; Andrews KL; Chmait S; Chen N; Clarine JG; Davis C; Eastwood HA; Horne DB; Hu E; Jones AD; Kaller MR; Kunz RK; Miller S; Monenschein H; Nguyen T; Pickrell AJ; Porter A; Reichelt A; Zhao X; Treanor JJS; Allen JR
Bioorg Med Chem; 2014 Dec; 22(23):6570-6585. PubMed ID: 25456383
[TBL] [Abstract][Full Text] [Related]
15. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A).
Hu E; Kunz RK; Chen N; Rumfelt S; Siegmund A; Andrews K; Chmait S; Zhao S; Davis C; Chen H; Lester-Zeiner D; Ma J; Biorn C; Shi J; Porter A; Treanor J; Allen JR
J Med Chem; 2013 Nov; 56(21):8781-92. PubMed ID: 24102193
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Raheem IT; Schreier JD; Fuerst J; Gantert L; Hostetler ED; Huszar S; Joshi A; Kandebo M; Kim SH; Li J; Ma B; McGaughey G; Sharma S; Shipe WD; Uslaner J; Vandeveer GH; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
Bioorg Med Chem Lett; 2016 Jan; 26(1):126-32. PubMed ID: 26602277
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety.
Koizumi Y; Tanaka Y; Matsumura T; Kadoh Y; Miyoshi H; Hongu M; Takedomi K; Kotera J; Sasaki T; Taniguchi H; Watanabe Y; Takakuwa M; Kojima K; Baba N; Nakamura I; Kawanishi E
Bioorg Med Chem; 2019 Aug; 27(15):3440-3450. PubMed ID: 31235264
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
